--- title: "Altimmune | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286311863.md" datetime: "2026-05-13T20:23:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286311863.md) - [en](https://longbridge.com/en/news/286311863.md) - [zh-HK](https://longbridge.com/zh-HK/news/286311863.md) --- # Altimmune | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 1.11 K. EPS: As of FY2026 Q1, the actual value is USD -0.18, beating the estimate of USD -0.2479. EBIT: As of FY2026 Q1, the actual value is USD -26.08 M. #### Revenue Revenues were $0 for 2026, compared to $5 thousand for 2025, representing a decrease of $5 thousand or 100%. #### Operating Expenses Total operating expenses increased by $2,424 thousand, or 11%, to $24,244 thousand in 2026 from $21,820 thousand in 2025. **Research and Development (R&D)**: R&D expenses increased by $365 thousand, or 2%, to $16,192 thousand in 2026 from $15,827 thousand in 2025. This increase was primarily due to ongoing ALD and AUD trials and startup costs for the PERFORMA Phase 3 MASH trial, partially offset by decreased expenses from the completed IMPACT Phase 2b MASH trial. MASH-related R&D decreased by $2,620 thousand, or 41%, to $3,697 thousand in 2026 from $6,317 thousand in 2025. ALD-related R&D increased to $2,635 thousand in 2026 from $58 thousand in 2025. AUD-related R&D increased by $1,241 thousand, or 393%, to $1,557 thousand in 2026 from $316 thousand in 2025. Other pemvidutide expenses decreased by $898 thousand, or 35%, to $1,642 thousand in 2026 from $2,540 thousand in 2025. Non-project labor costs increased by $143 thousand, or 4%, to $3,488 thousand in 2026 from $3,345 thousand in 2025. Stock compensation (R&D portion) decreased by $544 thousand, or 31%, to $1,232 thousand in 2026 from $1,776 thousand in 2025. Shared service and infrastructure costs increased by $466 thousand, or 32%, to $1,941 thousand in 2026 from $1,475 thousand in 2025. **General and Administrative (G&A)**: G&A expenses increased by $2,059 thousand, or 34%, to $8,052 thousand in 2026 from $5,993 thousand in 2025, mainly due to a $1.3 million increase in compensation expense and a $0.6 million increase in professional service fees. #### Loss from Operations Loss from operations increased by $2,429 thousand, or 11%, to - $24,244 thousand in 2026 from - $21,815 thousand in 2025. #### Other Income (Expense), Net Total other income (expense), net increased by $122 thousand, or 8%, to $1,681 thousand in 2026 from $1,559 thousand in 2025. Interest expense increased by $1,067 thousand to - $1,068 thousand in 2026 from - $1 thousand in 2025. Interest income increased by $1,356 thousand, or 88%, to $2,901 thousand in 2026 from $1,545 thousand in 2025. Other income (expense), net decreased by $167 thousand to - $152 thousand in 2026 from $15 thousand in 2025. #### Net Loss Net loss increased by $2,988 thousand, or 15%, to - $22,563 thousand in 2026 from - $19,575 thousand in 2025.Net loss before income taxes increased by $2,307 thousand, or 11%, to - $22,563 thousand in 2026 from - $20,256 thousand in 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $20,942 thousand in 2026, compared to - $16,840 thousand in 2025, an increase in cash used of $4,102 thousand. - **Net Cash Used in Investing Activities**: Net cash used in investing activities was - $3,690 thousand in 2026, compared to - $5,101 thousand in 2025, primarily due to $43.3 million in purchases of short-term investments, partially offset by $39.6 million from sales and maturities of short-term investments in 2026. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was $78,473 thousand in 2026, compared to $34,119 thousand in 2025, mainly driven by $70.3 million in net proceeds from a January 2026 Registered Direct Offering (RDO) and $8.7 million from at-the-market (ATM) offerings in 2026. #### Financial Position - **Cash, Cash Equivalents, Restricted Cash and Short-term Investments**: $331.6 million as of March 31, 2026. - **Accumulated Deficit**: - $672.0 million as of March 31, 2026. #### Future Outlook and Strategy Altimmune, Inc. plans to initiate its PERFORMA Phase 3 trial for MASH in the second half of 2026 and expects to announce topline results for the RECLAIM Phase 2 AUD trial in the third quarter of 2026. The company anticipates completing enrollment for the RESTORE Phase 2 ALD trial in the third quarter of 2026. Altimmune, Inc. believes its current cash and cash equivalents, combined with expected cash receipts from equity transactions, are sufficient to fund operations for at least a twelve-month period from the issuance date of its March 31, 2026 consolidated financial statements. ### Related Stocks - [ALT.US](https://longbridge.com/en/quote/ALT.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [REEVES CONFIRMS NO INCREASE IN UK FUEL DUTY IN 2026](https://longbridge.com/en/news/287213292.md)